Rana P. Singh

Rana P. Singh
Professor
Centre/School/Special Centre: 
School of Life Sciences
Room No: 
104
Off. Phone: 
011-26704503
Email: 
rana_singh@mail.jnu.ac.in , ranaps@hotmail.com
Personal Webpage: 
http://www.rpscancerlab.com/
Qualifications: 

Ph.D.

Areas of Interest/Specialization: 

Carcinogenesis, Cancer Chemoprevention and Therapeutics, Tumor Angiogenesis, Radiation Therapy, Anticancer Drug Development from Natural Agents

Experience: 

16 years 

Awards & Honours: 

* ICMR International Fellowship for Young Biomedical Scientists-2013-14. (University of California Riverside, USA)
* Post-doctoral Trainee Award for Prostate Cancer Research, U.S. Army Medical Research and Materiel Command, Department of Defense, USA. (2003)
* Scholar-in-Training Award, American Association for Cancer Research, Philadelphia, PA, USA. (2002)

Editorial Board Member:
1. Molecular Cancer Biology - Editor (2012- )
2. PLoS One - Academic Editor (2011- )
3. BMC Cancer - Associate Editor - Basic Research (2013- )
4. Frontiers in Cellular Biochemistry - Review Editor (2013- ) 

International Collaboration/Consultancy: 

1. School of Pharmacy, University of Colorado Denver, CO, USA.
2. College of Pharmacy, Sahmyook University, Seoul, South Korea. 
3. Department of Pharmacology and Chemical Biology, University of Pittsburgh, PA, USA

 

Final report of UGC project "To study the role of protein glycosylation in cell-extracellular matrix interaction and cancer progression"

Best Peer Reviewed Publications (upto 5): 

1. Nambiar DK, Rajamani P, Deep G, Jain AK, Agarwal R, Singh RP. Silibinin preferentially radiosensitizes prostate cancer by inhibiting DNA repair signaling. Molecular Cancer Therapeutics, 14; 2722-34, 2015.

2. Tailor D, Hahm ER, Kale RK, Singh SV, Singh RP. Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells. Mitochondrion, 16; 55-64, 2014.

3. Jhala DV, Kale RK, Singh RP. Microgravity alters cancer growth and progression. Current Cancer Drug Targets, 14; 394-406, 2014.

4. Nambiar D, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibit aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget, 5; 10017-33, 2014.

5. Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo: Implications for angioprevention. Carcinogenesis, 33; 385-93, 2012.

Recent Peer Reviewed Journals/Books (upto 3): 

Book:
1. Breast Cancer – Biology, Prevention and Treatment. 
A.R. Rao and Rana P. Singh. Red Flower Publication, New Delhi, 2015.

Guest Editor for Special Issues:
1. Mitochondrion (May, 2014) – Role of Mitochondria in Health and Disease
2. Nutrition and Cancer (May, 2013) – Mechanisms of Bioactive Phytochemicals in Cancer Chemoprevention
3. Indian Journal of Experimental Biology (Nov. 2011) - Emerging Trends in Cancer: Prevention and Therapeutics 

Patents (if any): 

Singh RP, Nambiar D, Agarwal R. “A novel and selective radiosensitizing agent for providing mechanism-based radiosensitizing effects in prostate cancer”. Patent files, application no. 2889/del/2015.